Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over. NICE technology appraisal guidance 1147
National Institute for Health and Care Excellence (NICE)
Record ID 32018015230
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1147
Year Published:
2026
URL for published report:
https://www.nice.org.uk/guidance/ta1147
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Astrocytoma
- Oligodendroglioma
- Brain Neoplasms
- Adult
- Adolescent
- Enzyme Inhibitors
- Glioma
- Spinal Cord Neoplasms
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.